This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mikulic, E. Articles by Franciosa, J. A. Search for Related Content PubMed PubMed Citation Articles by Mikulic, E. Articles by Franciosa, J. A.

Circulation, Vol 56, 528-533, Copyright © 1977 by American Heart Association

ARTICLES

Comparative hemodynamic effects of inotropic and vasodilator drugs in severe heart failure

E Mikulic, JN Cohn and JA Franciosa

In 12 patients with severe congestive heart failure (CHF) due to ischemic heart disease or nonischemic cardiomyopathy the hemodynamic response to intravenous infusion of sodium nitroprusside (N) was compared to that of dobutamine (D) 10 microgram/kg/min. D and N produced comparable increases in cardiac output (CO) (2.8 to 5.8 L/min and 2.9 to 5.0 L/min, respectively), but, compared to N, D caused a higher arterial pressure (99.3 vs 86.2 mm Hg, P less than 0.01) and heart rate (102.5 vs 95.3, P less than 0.05) and less reduction in pulmonary wedge pressure (PWP) (28.9 to 20.2 mm Hg vs 29.1 to 16.6 mm Hg, P less than 0.05). In five additional patients N and D were studied separately and then were infused together. The combination resulted in a higher CO, lower PWP and greater reduction in systemic and pulmonary vascular resistances than either drug alone. Brachial arterial infusion of nitroprusside produced prominent forearm vasodilation in a dose less than 10% of the systemic dose, whereas vasodilation with dobutamine was only modest even when 50% of the systemic dose was infused. Therefore, potent inotropic and vasodilator drugs produce similar and additive augmentation to left ventricular performance in heart failure. Reduction in vascular resistance with dobutamine probably is largely of reflex origin, but the vasodilation itself may be an important determinant of the rise in cardiac output.

This article has been cited by other articles:

				J. N. Cohn Blood pressure and the therapy of advanced heart failure J. Am. Coll. Cardiol., April 21, 2004; 43(8): 1430 - 1431. [Full Text] [PDF]

				S. Kasama, T. Toyama, H. Hoshizaki, S. Oshima, K. Taniguchi, T. Suzuki, and M. Kurabayashi Dobutamine Gated Blood Pool Scintigraphy Predicts the Improvement of Cardiac Sympathetic Nerve Activity, Cardiac Function, and Symptoms After Treatment in Patients With Dilated Cardiomyopathy* Chest, August 1, 2002; 122(2): 542 - 548. [Abstract] [Full Text] [PDF]

				M. A. Matthay and K. Chatterjee Bedside Catheterization of the Pulmonary Artery: Risks Compared with Benefits Ann Intern Med, November 15, 1988; 109(10): 826 - 834. [Abstract] [PDF]

				C. V. LEIER and D. V. UNVERFERTH Drugs Five Years Later: Dobutamine Ann Intern Med, October 1, 1983; 99(4): 490 - 496. [Abstract] [PDF]

				J. N. COHN and L. P. BURKE Nitroprusside Ann Intern Med, November 1, 1979; 91(5): 752 - 757. [Abstract] [PDF]

				P. Reyns, D. Romney, K. B. Desser, and A. Benchimol Serial Hemodynamic Studies During the Treatment of Congestive Heart Failure With Isolated Low-Dose Oral Prazosin Therapy Angiology, January 1, 1979; 30(12): 850 - 855. [Abstract] [PDF]

				G. L. Pierpont, J. N. Cohn, and J. A. Franciosa Congestive Cardiomyopathy: Pathophysiology and Response to Therapy Arch Intern Med, December 1, 1978; 138(12): 1847 - 1850. [Abstract] [PDF]